Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $99,994.40 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 968 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $99,994.40. Following the completion of the sale, the senior vice president directly owned 4,503 shares of the company’s stock, valued at approximately $465,159.90. This trade represents a 17.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total value of $80,991.98.
• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $86,423.58.

Mirum Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ:MIRM traded up $1.65 during trading on Tuesday, reaching $105.45. 670,739 shares of the company traded hands, compared to its average volume of 775,404. The firm has a market capitalization of $5.42 billion, a price-to-earnings ratio of -122.61 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $105.64. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The business’s fifty day moving average is $81.60 and its 200-day moving average is $73.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same period in the previous year, the firm earned ($0.30) earnings per share. The firm’s revenue for the quarter was up 47.1% on a year-over-year basis. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. MCF Advisors LLC raised its position in shares of Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the third quarter worth $33,000. Quarry LP bought a new position in Mirum Pharmaceuticals in the third quarter worth $41,000. CWM LLC lifted its position in Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after buying an additional 161 shares during the period. Finally, Comerica Bank lifted its position in Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares during the period.

Analyst Ratings Changes

Several equities analysts have recently commented on MIRM shares. Citizens Jmp upped their price objective on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research note on Friday, December 19th. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Raymond James Financial reiterated a “strong-buy” rating and issued a $110.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. Finally, Leerink Partners set a $100.00 target price on Mirum Pharmaceuticals in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $107.25.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.